Overview |
bsm-52009r |
ADAM17 Recombinant Antibody |
WB, FCM, IF(ICC) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Recombinant human ADAM17 protein, around 700-824aa. |
700-824/824 |
Monoclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
Target |
6868 |
P78536 |
Disintegrin and metalloproteinase domain-containing protein 17; ADAM metallopeptidase domain 17; CSVP; TACE; NISBD; CD156B; NISBD1; Snake venom-like protease; TNF-alpha convertase; TNF-alpha-converting enzyme; Tumor Necrosis Factor Alpha Converting Enzyme. |
Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(ICC) |
1:50-200 |